itasetron
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 1998 (NCT02259985)
Timeline
1990s
- Jan 1, 1998
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serotonin 3a (5-HT3a) receptorINHIBITOR
HTR3A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CN1[C@@H]2CC[C@H]1C[C@@H](NC(=O)n1c(=O)[nH]c3ccccc31)C2- Mol. weight
- 300.36 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2105109 ↗
Also known as
- dau 6215
- dau6215cl
- dau6215cl
- (endo-n-8-methyl-8-azabicyclo(3.2.1.)-oct-3-yl)-2,3-dihydro-2-oxo-1h-benzimidazol-1-carboxamide
- itasetron
- itasetron
- itasetron
- itasetron
- itasetron hydrochloride
- n-(8-methyl-8-azabicyclo (3.2.1.)oct-3-yl)2,3-dihydro-2-oxo-1h-benzimidazole-1-carboxamide
- u 98079a
- u-98079a
- u-98079a
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02259985 | Phase 1 | Mar 1, 1998 | Boehringer Ingelheim |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 1 | 1 | 1 | 1998 |
1 organizations
Page 1 / 1